ライフサイエンスコーパス: microchimerism

1 r decades, and create a state of physiologic microchimerism.

2 ically distinct individual is referred to as microchimerism.

3 ctors potentially associated with persistent microchimerism.

4 factor-alpha 308A allele and maternal fetal microchimerism.

5 that influence the development of fetal cell microchimerism.

6 ssed the relationship among DQA1 alleles and microchimerism.

7 ate into the host and establish long-lasting microchimerism.

8 tro immune responses in mice with persistent microchimerism.

9 cond donor kidney graft and establishment of microchimerism.

10 in the fetal circulation, known as maternal microchimerism.

11 pendent upon the presence of donor-recipient microchimerism.

12 jection can occur in spite of donor-specific microchimerism.

13 re invasive disease were deficient for fetal microchimerism.

14 l cells in her offspring, a process known as microchimerism.

15 rtaken to investigate rheumatoid nodules for microchimerism.

16 ients who lack the SE can acquire it through microchimerism.

17 espite prolonged graft survival and pig cell microchimerism.

18 uma patients develops transfusion-associated microchimerism.

19 on appeared to be due to persistent pig cell microchimerism.

20 n of infectious agents and the potential for microchimerism.

21 tolerance to organs based on fetal-maternal microchimerism.

22 es on the X chromosomes and, secondly, fetal microchimerism.

23 Development of sustained microchimerism after transfusion in HIV-infected patient

24 induced immune modulation and development of microchimerism after transfusion of trauma patients.

25 Considering findings of naturally acquired microchimerism along with iatrogenic microchimerism sugg

26 t MHC genotype is associated with persistent microchimerism among T lymphocytes in women with sclerod

27 Fetal microchimerism among T lymphocytes was strongly associat

28 using FL-mobilized bone marrow (BM) cells on microchimerism and anti-donor reactivity in normal and t

29 ative conditioning and resulted in transient microchimerism and clinical and virologic improvements.

30 even mother-son pairs were also analyzed for microchimerism and DQA1*0501.

31 aintained in the absence of detectable donor microchimerism and in the presence of anti-donor reactiv

32 t allograft survival This is associated with microchimerism and inhibition of antidonor cytotoxic T l

33 In control experiments, a rank order of microchimerism and of associated donor specific nonreact

34 clinical parameters, the association between microchimerism and pulmonary function was the most strik

35 4 treatment blocked the development of donor microchimerism and recovered the ability of mice to prol

36 that EVs provide a physiologic link between microchimerism and split tolerance, with implications fo

37 An association has been reported between microchimerism and the development of tolerance.

38 further our understanding of fetal:maternal microchimerism and the role of fetal cells in maternal h

39 r there is an association between fetal cell microchimerism and thyroid disease in women.

40 ndings suggest a relation between fetal cell microchimerism and thyroid disease.

41 allows the differentiation between pig cell microchimerism and true xenogeneic infection.

42 The biological significance of maternal microchimerism and whether it might contribute to autoim

43 in the maternal circulation, known as fetal microchimerism, and maternal cells in the fetal circulat

44 ernal alleles that may work through maternal microchimerism, and sex-specific epigenetic mechanisms o

45 Microchimerism (approximately 1:75,000 cells) was observ

46 Studies on microchimerism are unraveling interesting associations i

47 Modeling the level of quantitative microchimerism as a rate via Poisson or negative binomia

48 ection episodes in patients with and without microchimerism as defined by detectable donor DR genes.

49 resent an excellent model for study of fetal microchimerism, as they share our environment, have a na

50 t high levels of peripheral blood allogeneic microchimerism at 12 to 18 months posttransplant correla

51 The degree of microchimerism at 60 and 110 days was estimated with sem

52 ng-dilution PCR to quantify peripheral blood microchimerism at serial timepoints ranging from 3 to >4

53 the single donor implicated as the source of microchimerism by HLA typing.

54 isease susceptibility, our data suggest that microchimerism by itself does not play a significant rol

55 Rheumatoid nodules were tested for microchimerism by real-time quantitative polymerase chai

56 ardiac myocytes) raises the possibility that microchimerism can be a target of autoimmunity or altern

57 ars has raised the question of whether fetal microchimerism can cause subsequent disease in the mothe

58 Clinically, states of microchimerism can exist, but rejection still occurs.

59 long with iatrogenic microchimerism suggests microchimerism can have detrimental and/or beneficial ef

60 that differentiated tissue-specific maternal microchimerism can occur in neonates.

61 Microchimerism can persist long-term and has been associ

62 r findings is not known, HLA-disparate fetal microchimerism can persist many years after a birth and

63 Microchimerism concentrations were also higher in RA pat

64 Whether fetal microchimerism contributes to GVHD merits further invest

65 This article explores the hypothesis that microchimerism contributes to the pathogenesis of sclero

66 l cell exchange, suggesting that SE-encoding microchimerism could be a risk factor for RA.

67 No differences in microchimerism could be detected between the groups as d

68 This observation implies that maternal microchimerism could sometimes be involved in SLE and th

69 Quantitative microchimerism data present challenges for statistical a

70 most appropriate for analyzing quantitative microchimerism data.

71 eviewed all reports of studies on fetal cell microchimerism, defined as male DNA in maternal tissue,

72 cells may represent a human analogue of the microchimerism described in the mouse and may have signi

73 association of exposure or study group with microchimerism detection rates.

74 including those not given DBM, but levels of microchimerism did not correlate with graft survival.

75 Microchimerism disappeared after 1 year, and CD4(+)CD25(

76 Also, persisting microchimerism does not necessarily correlate with clini

77 Development of donor-specific microchimerism (DSM) has been proposed as one of the pos

78 either from naturally acquired or iatrogenic microchimerism (eg, cardiac myocytes) raises the possibi

79 Recent identification of tissue-specific microchimerism either from naturally acquired or iatroge

80 Fetal cell microchimerism (FCM) is the persistence of fetal cells i

81 s after delivery and is referred to as fetal microchimerism (FM).

82 Fetal microchimerism (FMc) describes long-term persistence of

83 preliminary evidence that dogs develop fetal microchimerism following pregnancy.

84 lack the SE can acquire the SE as persistent microchimerism from fetal-maternal cell exchange, sugges

85 We previously proposed that persistent fetal microchimerism from pregnancy contributes to the pathoge

86 Unequivocal eradication of donor leukocyte microchimerism from recipients of long-surviving organ t

87 tal groups, an attempt was made to eliminate microchimerism from the BN recipients.

88 the rate of detection defined as a count of microchimerism genome equivalents per total cell equival

89 Haemopoietic microchimerism has been identified in recipients of soli

90 For example, fetal microchimerism has been implicated in autoimmune disease

91 Microchimerism has been implicated in the etiology of au

92 In humans, naturally acquired microchimerism has been observed in many tissues and org

93 Fetal microchimerism has been suggested to play contradictory

94 Microchimerism has been theorized to be an important or

95 However, fetal microchimerism has not been described in dogs.

96 toimmune disease in which naturally acquired microchimerism has previously been described and can som

97 Naturally acquired microchimerism has recently been investigated in autoimm

98 Donor-recipient microchimerism has recently been suggested to play a cri

99 Fetal microchimerism, however, has not been investigated in th

100 Microchimerism (IAb+ cells) was demonstrated by immunocy

101 f the animals, which correlated with durable microchimerism in BM and spleen.

102 Polymerase chain reaction demonstrated microchimerism in both groups.

103 we evaluated for the presence of male fetal microchimerism in buffy coat cells from women with a pri

104 islet cells and should facilitate studies of microchimerism in experimental models of pig to monkey x

105 Here, we show maternal cells that establish microchimerism in female offspring during development pr

106 The role of donor-specific microchimerism in graft acceptance or graft tolerance re

107 also frequently revealed persistent maternal microchimerism in healthy control subjects.

108 The frequency of subsequent fetomaternal microchimerism in healthy women and its cell type is unk

109 til the discovery in 1992 of donor leukocyte microchimerism in long-surviving liver, and other kinds

110 l induction, peripheral blood chimerism, and microchimerism in lymphatic organs were analyzed.

111 ning pig kidney xenograft and persistence of microchimerism in lymphatic tissue after graft removal.

112 n of an association between persistent fetal microchimerism in maternal T lymphocytes and specific HL

113 g factor flt3 ligand (FL) on donor leukocyte microchimerism in noncytodepleted recipients of allogene

114 Accurate and sensitive detection of microchimerism in nonhuman primates (NHPs) after hematop

115 It is difficult to eliminate microchimerism in organ recipients once the donor cells

116 Microchimerism in PBMC subsets was not appreciably more

117 ibility was not a requirement for persistent microchimerism in PBMC subsets.

118 Although microchimerism in PBMC was more frequent in women with s

119 demonstrate an association of DQA1*0501 with microchimerism in peripheral blood DNA or T lymphocytes,

120 or irradiated splenocytes, resulted in donor microchimerism in peripheral lymphoid organs, with prefe

121 ngoing studies are evaluating the utility of microchimerism in predicting the risk of graft rejection

122 nalyses for SE type, the prevalence of QKRAA microchimerism in RA patients versus healthy controls wa

123 Although the persistence of multilineage microchimerism in recipients of long-surviving organ tra

124 ochimerism is genetically disparate, whether microchimerism in rheumatoid nodules serves as an alloge

125 Microchimerism in scleroderma patients could be secondar

126 1*0501 has been associated with T lymphocyte microchimerism in SSc.

127 al HLA genes to test for persistent maternal microchimerism in subjects with scleroderma and in healt

128 se of this study was to search for sustained microchimerism in such patients.

129 emonstrate that DQA1*0501 is associated with microchimerism in T lymphocytes or in whole peripheral b

130 Since RA patients harbor microchimerism in the blood, we hypothesized that microc

131 the females (37 of 59) tested harbored male microchimerism in the brain.

132 (p=0.03) and concentration (p=0.06) of male microchimerism in the brains of women with Alzheimer's d

133 Fetal microchimerism in the face of HLA disparity implies that

134 We detected high levels of donor microchimerism in the heart, kidney, liver, skin, bone m

135 appear to play a role in the persistence of microchimerism in the peripheral blood or T lymphocytes

136 ransplantation demonstrates peripheral blood microchimerism in the presence of a functioning pig kidn

137 nd recipient's HLA alleles did not influence microchimerism in the recipient.

138 cells during pregnancy and persistent fetal microchimerism in the rhesus model.

139 with donor B cells did not induce detectable microchimerism in this group of recipients.

140 rnal cells to detect and quantitate maternal microchimerism in tissues of neoR(-/-) N2 backcross prog

141 ned through knowledge garnered in studies of microchimerism in transplantation biology.

142 However, functional benefits of maternal microchimerism in utero are unknown.

143 identify and quantify tissue-specific fetal microchimerism in women with SSc.

144 sustained elevation of donor (I-Ab+) cells (microchimerism) in the spleen including T cell areas.

145 After its initial decline, microchimerism increased with FEV1 for the 1 hyporespons

146 ulations derived from different individuals; microchimerism indicates low levels of chimerism.

147 Kinder et al. find that maternal microchimerism induces stable immune tolerance to non-in

148 Microchimerism influenced by human leukocyte antigen als

149 g our more sensitive technology, showed that microchimerism is a very common event in human liver and

150 gh high-lighted in the study of scleroderma, microchimerism is also implicated in selected other auto

151 chimerism in the blood, we hypothesized that microchimerism is also present in rheumatoid nodules and

152 ata clearly demonstrate that the presence of microchimerism is common following administration of don

153 We conclude that donor microchimerism is found after intrathymic inoculation of

154 In conclusion, male microchimerism is frequent and widely distributed in the

155 Our findings indicate that microchimerism is frequently present in the rheumatoid n

156 Since microchimerism is genetically disparate, whether microch

157 We tested the hypothesis that microchimerism is involved in the pathogenesis of sclero

158 ot required for tolerance induction and that microchimerism is not an absolute requirement for the ge

159 engraftment, our data suggest that long-term microchimerism is not required to prevent chronic reject

160 oviding direct evidence that donor-recipient microchimerism is not sufficient for the prevention of a

161 Although such microchimerism is often associated with graft acceptance

162 se in tolerance induction in utero even when microchimerism is present.

163 e that at least short-term donor BMC-derived microchimerism is required for prolonged allograft survi

164 We asked whether male DNA (presumed fetal microchimerism) is present in apheresis products of fema

165 e been pregnant, a phenomenon known as fetal microchimerism, is emerging as a potential contributing

166 sfusion induced a low level of hematopoietic microchimerism, it did not strictly correlate with ameli

167 Methods for comparing microchimerism levels across groups while controlling fo

168 me, that the fluctuation of peripheral blood microchimerism levels is associated with the recipient's

169 s to determine any association of sequential microchimerism levels with concomitant clinical events.

170 Thus microchimerism may be common, and finding microchimeric

171 for controls, supports the possibility that microchimerism may be involved in the pathogenesis of sc

172 ng, we hypothesized that this fetal-maternal microchimerism may confer tolerance and thus less graft

173 responses, the maintenance of haploidentical microchimerism may impart an allogeneic edge in immunosu

174 ir offspring, our results indicate that this microchimerism may not improve renal allograft or patien

175 donor origin in organ transplant recipients (microchimerism) may influence allograft survival and may

176 Microchimerism (Mc) refers to the harboring of a small n

177 Microchimerism (MC), defined as the persistence of allog

178 Microchimerism (Mc), originating from bidirectional feta

179 Small amounts of genetically foreign cells (microchimerism, Mc) traffic between a mother and fetus d

180 We also asked whether persistent microchimerism might contribute to subsequent autoimmune

181 A mechanism by which microchimerism might contribute to the pathogenesis of s

182 Maternal microchimerism (MMc) has been associated with developmen

183 of maternal cells and DNA known as maternal microchimerism (MMc), and we hypothesized that PM increa

184 pring, a common occurrence known as maternal microchimerism (MMc).

185 n adult life, and is referred to as maternal microchimerism (MMc).

186 to maternal cells and antigens (eg, maternal microchimerism [MMc]).

187 itic cells (DCs), a prominent lineage in the microchimerism observed in rodents and clinical organ re

188 reaction (PCR) analysis to determine whether microchimerism occurred in patients who subsequently dev

189 ing age of the recipient, time elapsed since microchimerism occurred, and microchimeric cell type mod

190 We asked whether long-term fetal microchimerism occurs in T lymphocyte, B lymphocyte, mon

191 le dogs and these results suggest that fetal microchimerism occurs in the canine species.

192 unts of foreign cells or DNA, referred to as microchimerism, occurs primarily through maternal-fetal

193 ignificantly associated with the presence of microchimerism (odds ratio 2.4, 95% confidence interval

194 study was undertaken to investigate cellular microchimerism of either male or female origin in DNA fr

195 Cellular microchimerism of either male or female origin was detec

196 Because of the possibility of Y chromosome microchimerism of females with male offspring, we analyz

197 Microchimerism of fetal as well as maternal origin has r

198 It is possible that persistent microchimerism of fetal cells in maternal circulation ma

199 NA in the human female brain as a marker for microchimerism of fetal origin (i.e. acquisition of male

200 The influence of donor hematopoietic cell microchimerism on organ allograft survival has been stud

201 ted across species lines represents cellular microchimerism, ongoing viral infection, or uptake of fr

202 The results indicate that a state of microchimerism per se is insufficient for the induction

203 Pig cell microchimerism (pig major histocompatibility complex cla

204 udies will be necessary to determine whether microchimerism plays a role in the pathogenesis of this

205 We have postulated that the donor leukocyte microchimerism plays a seminal role in the acceptance of

206 s unclear whether this peripheral donor cell microchimerism plays an active role in graft acceptance

207 Persistent microchimerism (presence of donor cells in the recipient

208 ly caused by transmaternal cell flow of male microchimerism present in the mother.

209 Combined microchimerism prevalence was 47%.

210 ection occurred despite high levels of donor microchimerism, providing direct evidence that donor-rec

211 Microchimerism refers to a state in which donor cells pe

212 The significance of this microchimerism remains unclear, partially because of the

213 mend that investigators in future studies on microchimerism report detailed pregnancy information, si

214 merism, which raises the question of whether microchimerism sometimes contributes to autoimmune disea

215 ting a nonshared HLA allele of the potential microchimerism source.

216 pregnancy histories, disease diagnoses, and microchimerism status.

217 cquired microchimerism along with iatrogenic microchimerism suggests microchimerism can have detrimen

218 ass I alleles, thereby adding flexibility to microchimerism testing by enabling testing of recipients

219 s, brain tissue had higher level of maternal microchimerism than lymphoid tissue in mice MHC identica

220 zygous progeny had higher levels of maternal microchimerism than MHC heterozygous progeny.

221 Microchimerism, the stable presence of foreign cells in

222 ith transient systemic tacrolimus therapy on microchimerism, the survival of nonvascularized cardiac

223 the presence of chronic rejection and donor microchimerism to assess whether this regimen of immune

224 by the time course from occurrence of fetal microchimerism to the multi-factorial development of dis

225 IV infection are ostensibly at high risk for microchimerism, transfusion-associated graft-versus-host

226 drugs more than 12 years ago was tested for microchimerism using a sensitive nested polymerase chain

227 compared statistical models for quantitative microchimerism values, applied to simulated data sets an

228 The mean age of all subjects with maternal microchimerism was 28 years (range: 9-49 years).

229 of 34; P = 0.03) and the prevalence of QRRAA microchimerism was 40% versus 18% (21 of 52 versus 6 of

230 Donor microchimerism was also detected in unmanipulated contro

231 Donor microchimerism was analyzed using the polymerase chain r

232 Microchimerism was continuous by PCR up to 33 days.

233 Fetal microchimerism was detected in 75 of 88 controls (85%) a

234 In addition, HA-1 microchimerism was detected in two recipients, primarily

235 enigmatic until multilineage donor leukocyte microchimerism was discovered in 1992 in long-surviving

236 Overall, microchimerism was found in CD3, CD19, and CD14 subsets

237 Microchimerism was found in PBMC from 33% (16 of 48) of

238 Microchimerism was found in some women in CD3, CD19, CD1

239 Microchimerism was observed in all recipients studied, i

240 Polymerase chain reaction for microchimerism was performed on the host's marrow.

241 Male microchimerism was present in 6 of 12 UCB samples analyz

242 Male microchimerism was present in multiple brain regions.

243 After the TBI-reconstitution at 60 days, microchimerism was undetectable in BMC recipients at 110

244 or blood of long-surviving organ recipients (microchimerism), we concluded that organ engraftment was

245 ternal-fetal histocompatibility and maternal microchimerism, we developed a sensitive quantitative PC

246 Concentrations of SE microchimerism were also significantly higher among RA p

247 The highest levels of splenic microchimerism were found in mice with long surviving gr

248 mothers of subjects with persistent maternal microchimerism were HLA incompatible with subjects for c

249 The effects of microchimerism were neutralized by bone marrow transplan

250 Tacrolimus markedly enhanced microchimerism, which declined as a function of time.

251 d in order to avoid confounding due to fetal microchimerism, which may occur in women.

252 er during pregnancy can lead to long-lasting microchimerism, which raises the question of whether mic

253 We observed dynamic patterns of peripheral microchimerism, which reflected the general rise and fal

254 Therefore, analysis of microchimerism with a single, post-transplant analysis m

255 Microchimerism with the SE was found significantly more

256 The status of donor microchimerism, with respect to its presence and tissue

257 dly, a few rheumatoid nodules also contained microchimerism without evidence of a fetal or maternal s

258 ore examined whether inducing hematolymphoid microchimerism without myeloablation could confer the ab